Loading...
•
Mar 31
Enliven Therapeutics Q1 2025 Earnings Report
Enliven Therapeutics reported its first quarter financial results for 2025, highlighting progress in its clinical trials and a strong financial position.
Key Takeaways
Enliven Therapeutics reported a net loss of $28.5 million for the first quarter of 2025, an increase from the $22.7 million net loss in the same period last year. The company maintained a strong balance sheet with $289.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into late 2027. Key clinical updates include positive data from the ELVN-001 trial in CML and plans to explore strategic alternatives for the ELVN-002 program.
Net loss for Q1 2025 was $28.5 million, compared to $22.7 million in Q1 2024.
Cash, cash equivalents, and marketable securities totaled $289.6 million as of March 31, 2025, providing a cash runway into late 2027.
Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML will be presented at the EHA 2025 Congress in June, showing a cumulative MMR rate of 44% by 24 weeks.
Enliven plans to explore strategic alternatives for the ELVN-002 program and does not intend to pursue its development beyond 2025 to prioritize ELVN-001.
Enliven Therapeutics
Enliven Therapeutics
Forward Guidance
Enliven Therapeutics expects its current cash, cash equivalents, and marketable securities to provide a cash runway into late 2027. The company is focused on clinical execution for ELVN-001 and preparing for a potential pivotal trial in 2026, while exploring strategic alternatives for ELVN-002.
Positive Outlook
- Strong balance sheet with $290 million in cash, cash equivalents, and marketable securities expected to provide cash runway into late 2027.
- Continued progress of ELVN-001 with efficacy, safety, and tolerability data comparing favorably to approved BCR::ABL inhibitors.
- Further updated data for ELVN-001 to be shared at EHA next month.
- Focus on clinical execution for ELVN-001 and preparation for potential pivotal trial in 2026.
- ELVN-001 continues to demonstrate a favorable safety and tolerability profile.
Challenges Ahead
- Net loss increased to $28.5 million in Q1 2025 from $22.7 million in Q1 2024.
- Research and development expenses increased to $24.9 million in Q1 2025 from $20.0 million in Q1 2024.
- General and administrative expenses increased to $6.8 million in Q1 2025 from $6.0 million in Q1 2024.
- The company plans to explore strategic alternatives for the ELVN-002 program and does not intend to pursue its development beyond 2025.
- The company has not performed any head-to-head trials for ELVN-001, so conclusions from cross-trial comparisons cannot be made.